A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol
Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the effectiveness of atorvastatin in lowering
cholesterol and getting these high risk patients to their goals of LDL <115 mg/dl across
starting doses of 10 mg, 20 mg, or 40 mg with one step titration.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.